USA flag logo/image

An Official Website of the United States Government

DOMAIN-SPECIFIC ANTIBODIES TO HUMAN ERB-2/NEU PROTEIN

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
11130
Program Year/Program:
1990 / SBIR
Agency Tracking Number:
11130
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Molecular Oncology Inc
19 Firstfield Rd Gaithersburg, MD 20878
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 1990
Title: DOMAIN-SPECIFIC ANTIBODIES TO HUMAN ERB-2/NEU PROTEIN
Agency: HHS
Contract: N/A
Award Amount: $447,480.00
 

Abstract:

IN 20 TO 40 PERCENT OF HUMAN BREAST CANCERS, THE ERBB-2 OR NEU GENE IS AMPLIFIED, LEADING TO MRNA AND PROTEIN OVEREXPRESSION. THIS OVEREXPRESSION IS LIKELY TO BE INVOLVED IN EITHER THE INITIATION OR PROGRESSION OF THESE TUMOR CELLS. AMPLIFICATION OF THE ERBB-2 GENE HAS BEEN LINKED TO A POORER PROGNOSIS. IN PHASE I, MONOCLONAL AND POLYCLONAL ANTIBODIES TO EXTRACELLULAR AS WELL AS INTRACELLULAR REGIONS OF THE ERBB-2 PROTEIN WILL BE GENERATED. ANTIGEN WILL BE PREPARED FROM TWO SOURCES: MOUSE FIBROBLASTS EXPRESSING LARGE AMOUNTSOF THE HUMAN ERBB-2 PROTEIN AND BACTERIA GENETICALLY ENGINEERED TO EXPRESS SPECIFIC REGIONS OF THE ERBB-2 PROTEIN. THE RESULTING ANTIBODY PREPARATIONS WILL BE TESTEDFOR THEIR ABILITY TO SPECIFICALLY RECOGNIZE HUMAN ERBB-2 PROTEIN. IN PHASE II, THE USES OF THESE ANTIBODIES IN DIAGNOSIS AND THERAPY OF BREAST CANCER WILL BE EXPLORED.

Principal Investigator:


0

Business Contact:

Small Business Information at Submission:

Molecular Oncology Inc.
19 Firstfield Rd Gaithersburg, MD 20878

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No